IP Library Granted Patent US 7,829,596
Granted Patent B2
US 7,829,596 · App. 12/192,780 · Granted Nov 9, 2010

Methods of treatment

Assignee: Imperial Innovations Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,829,596
App. No.
12/192,780
Granted
Nov 9, 2010
Kind
B2
Abstract

A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidize inhibitor. The methods are particularly useful in treating cardiac cachexia.

Claims (5)

1. A method of treating cachexia in a patient, the method comprising administering to the patient an effective amount of a xanthine oxidase inhibitor to reduce sympathetic nervous system activity.

2. The method according to claim 1 wherein the xanthine oxidase inhibitor is any one of allopurinol, 7,8-dihydroneopterin, 5,6,7,8-tetrahydrobiopterin, leukopterin, xanthopterin, neopterin, biopterin, 4-amino-6-hydroxypyrazolo [3,4-d]pyrimidine (AHPP) and oxypurinol.

3. The method according to claim 1 wherein the cachexia occurs in a patient with an underlying disease selected from the group consisting of AIDS, liver cirrhosis, chronic obstructive pulmonary disease with or without emphysema, chronic renal failure, chronic infections, cancer, heart disease including hypertension and chronic heart failure.

4. The method according to claim 1 wherein the patient has idiopathic cachexia.

5. The method according to claim 1 wherein the cachexia occurs in a patient with chronic heart failure and the cachexia is cardiac cachexia.

Assignments (3)
CHANGE OF NAME Recorded Sep 29, 2010
From: IMPERIAL COLLEGE INNOVATIONS LIMITED
To: IMPERIAL INNOVATIONS LIMITED
Reel/Frame 025061/0456 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2008
From: ANKER, STEFAN DIETMAR; COATS, ANDREW JUSTIN STEWART
To: IMPERIAL COLLEGE INNOVATIONS LIMITED
Reel/Frame 021455/0581 →
CHANGE OF NAME Recorded Aug 28, 2008
From: IMPERIAL COLLEGE INNOVATIONS LIMITED
To: IMPERIAL INNOVATIONS LIMITED
Reel/Frame 021455/0599 →
Priority Claims (3)
GB 9822458.7 · Oct 15, 1998 · national
GB 9822459.5 · Oct 15, 1998 · national
GB 9917181.1 · Jul 23, 1999 · national
Continuity (2)
Division 0980755800
Related Publication 20090023639A1 · Jan 22, 2009